All In Biotech

Drug Trial Radar · NCT05057494

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 607 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

607

Actual

Start

Sep 12, 2022

Primary completion

Jul 15, 2027

Study completion Apr 10, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Conditions

  • Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Interventions

  • AcalabrutinibDrug

    Dose formulation: Capsule or Tablet

  • VenetoclaxDrug

    Dose formulation: Tablet

  • ObinutuzumabDrug

    Dose formulation: Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Until progressive disease (PD) [assessed Up to 6.6 Years].

Locations

37 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona

  • Research Site

    La Jolla, California

  • Research Site

    Longmont, Colorado

  • Research Site

    Jacksonville, Florida

  • Research Site

    Boston, Massachusetts

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Buffalo, New York

  • Research Site

    New Hyde Park, New York

  • Research Site

    New York, New York

  • Research Site

    Rochester, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Eugene, Oregon

  • Research Site

    Nashville, Tennessee

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Seattle, Washington

  • Research Site

    Clayton, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    Waratah, Australia

  • Research Site

    Hradec Králové, Czechia

  • Research Site

    Ostrava - Poruba, Czechia

  • Research Site

    Pilsen, Czechia

  • Research Site

    Montpellier, France

  • Research Site

    Tours, France

  • Research Site

    Budapest, Hungary

  • Research Site

    Debrecen, Hungary

  • Research Site

    Bydgoszcz, Poland

  • Research Site

    Gdansk, Poland

  • Research Site

    Katowice, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Lódz, Poland

  • Research Site

    Lublin, Poland

  • Research Site

    Barcelona, Spain

  • Research Site

    Palma de Mallorca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.